公开(公告)号：WO2012093127A3

公开(公告)日：2012-10-04

申请号：PCT/EP2012050066

申请日：2012-01-04

Applicant: UNIV ZUERICH ,  CHARITE UNIVERSITAETSMEDIZIN ,  BECHER BURKHARD ,  HEPPNER FRANK

Inventor： BECHER BURKHARD ,  HEPPNER FRANK

IPC: C07K16/18 ,  A61P25/28

CPC classification number: C07K16/244 ,  A61K31/202 ,  A61K31/5377 ,  A61K38/1793 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/92 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2320/30 ,  G01N33/502 ,  G01N33/5058

Abstract: The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like- molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R- ß1, IL-12R-ß2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.

Abstract translation: 本发明提供了抗p40，IL-12或IL-23的抗体，用于预防或治疗阿尔茨海默氏病。 它进一步提供了一对白细胞介素12或23及其特异性受体，特别是抗体，抗体片段，抗体样分子，用于预防或治疗阿尔茨海默氏病的配体。 类似地，提供了用于预防或治疗阿尔茨海默氏病的p19，p35，p40，IL-12R-β1，IL-12R-β2和/或IL-23R的基因表达的siRNA，反义或转录因子调节剂。

公开(公告)号：WO2007096396A2

公开(公告)日：2007-08-30

申请号：PCT/EP2007051692

申请日：2007-02-21

Applicant: UNIV ZUERICH ,  BECHER BURKHARD

Inventor： BECHER BURKHARD

IPC: C07K16/28 ,  A61P25/02

CPC classification number: C07K16/28

Abstract: The present invention relates to novel therapeutic or prophylactic treatment in human subjects. The present invention results in part from the discovery that antagonists of IL-18Ra are effective in vivo for treating diseases. Accordingly, the invention provides a method of treating, preventing or ameliorating the symptoms of an autoimmune or demyelinating disease (such as multiple sclerosis) in a subject, preferably a human subject, said method comprising administering to the subject a therapeutically effective amount of an antagonist of IL-18Ra. The invention also pertains to the use of an antagonist of IL-18Ra in the manufacture of a medicament for the treatment of an autoimmune or demyelinating diseases (such as multiple sclerosis).

Abstract translation: 本发明涉及在人受试者中的新型治疗或预防性治疗。 本发明部分源于IL-18Ra拮抗剂在体内有效治疗疾病的发现。 因此，本发明提供了治疗，预防或改善受试者，优选人受试者中自身免疫或脱髓鞘疾病（例如多发性硬化症）的症状的方法，所述方法包括向受试者施用治疗有效量的拮抗剂 的IL-18Ra。 本发明还涉及IL-18Ra拮抗剂在制备用于治疗自身免疫疾病或脱髓鞘疾病（例如多发性硬化症）的药物中的用途。

公开(公告)号：WO2007096396A3

公开(公告)日：2007-08-30

申请号：PCT/EP2007/051692

申请日：2007-02-21

Applicant: UNIVERSITY OF ZURICH ,  BECHER, Burkhard

Inventor： BECHER, Burkhard

IPC: C07K16/28 ,  A61P25/02

Abstract: The present invention relates to novel therapeutic or prophylactic treatment in human subjects. The present invention results in part from the discovery that antagonists of IL-18Rα are effective in vivo for treating diseases. Accordingly, the invention provides a method of treating, preventing or ameliorating the symptoms of an autoimmune or demyelinating disease (such as multiple sclerosis) in a subject, preferably a human subject, said method comprising administering to the subject a therapeutically effective amount of an antagonist of IL-18Rα. The invention also pertains to the use of an antagonist of IL-18Rα in the manufacture of a medicament for the treatment of an autoimmune or demyelinating diseases (such as multiple sclerosis).

公开(公告)号：WO2013053775A1

公开(公告)日：2013-04-18

申请号：PCT/EP2012/070088

申请日：2012-10-10

Applicant: UNIVERSITÄT ZÜRICH PROREKTORAT MNW ,  BECHER, Burkhard

Inventor： BECHER, Burkhard

IPC: A61K38/20 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K14/5434 ,  A61K9/0019 ,  A61K38/20 ,  A61K38/208 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/10041 ,  C12N2710/16041 ,  C12N2750/14041 ,  C12N2800/22 ,  A61K2300/00

Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.

Abstract translation: 本发明涉及用于治疗恶性肿瘤性疾病的组合药物。 组合药物包含具有IL-12生物学活性的IL-12多肽或包含编码这种IL-12多肽的序列的核酸表达载体和非激动剂CTLA-4配体或非激动剂PD-1配体 ，特别是抗CTLA-4或抗-PD-1免疫球蛋白G.

公开(公告)号：WO2013045033A1

公开(公告)日：2013-04-04

申请号：PCT/EP2012/003818

申请日：2012-09-12

Applicant: MERCK PATENT GMBH ,  BECHER, Burkhard ,  HENZLER, Tanja ,  HERGET, Thomas ,  WUENSCHE, Verena ,  ZENKE, Frank ,  SCHACHE, Janet

Inventor： BECHER, Burkhard ,  HENZLER, Tanja ,  HERGET, Thomas ,  WUENSCHE, Verena ,  ZENKE, Frank ,  SCHACHE, Janet

IPC: G01N33/50

CPC classification number: G01N33/5008 ,  G01N33/5014

Abstract: The present invention is directed to a method and assay with which certain cellular parameters can be determined. This method and assay provides an effective means for assessing drug candidate liabilities (toxicities and side effects) to better predict safety early in the drug development process.

Abstract translation: 本发明涉及可以确定某些细胞参数的方法和测定。 该方法和测定法为评估药物候选药物负荷（毒性和副作用）提供了有效的手段，以更好地预测药物开发过程的早期安全性。

公开(公告)号：WO2012093127A2

公开(公告)日：2012-07-12

申请号：PCT/EP2012/050066

申请日：2012-01-04

Applicant: UNIVERSITÄT ZÜRICH ,  CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN ,  BECHER, Burkhard ,  HEPPNER, Frank

Inventor： BECHER, Burkhard ,  HEPPNER, Frank

IPC: C07K16/18 ,  A61P25/28

CPC classification number: C07K16/244 ,  A61K31/202 ,  A61K31/5377 ,  A61K38/1793 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/92 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2320/30 ,  G01N33/502 ,  G01N33/5058

Abstract: The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like- molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R- β1, IL-12R-β2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.

Abstract translation: 本发明提供针对p40，IL-12或IL-23的抗体用于预防或治疗阿尔茨海默氏病。 它进一步为白介素12或23对及其特异性受体，特别是抗体，抗体片段，抗体样分子提供配体，用于预防或治疗阿尔茨海默氏病。 类似地，提供了用于预防或治疗阿尔茨海默病的p19，p35，p40，IL-12R-β1，IL-12R-β2和/或IL-23R的基因表达的siRNA，反义或转录因子调节剂。 p>

公开(公告)号：WO2007096398A1

公开(公告)日：2007-08-30

申请号：PCT/EP2007/051695

申请日：2007-02-21

Applicant: UNIVERSITY OF ZURICH ,  BECHER, Burkhard ,  SALLER, Elisabeth

Inventor： BECHER, Burkhard ,  SALLER, Elisabeth

IPC: C07K14/715 ,  A61K38/17 ,  C12N15/12 ,  A61P37/02

CPC classification number: C07K14/7155 ,  A61K38/00

Abstract: The present invention relates to novel therapeutic protein useful in the treatment of diseases, in particular in human subjects. The results of the inventor strongly support the use of soluble IL-18Rα in the treatment of diseases such as autoimmune or demyelinating disease, in particular Multiple Sclerosis (MS). Accordingly, the invention provides soluble IL-18Rα for use in the treatment of autoimmune or demyelinating disease, in particular MS. The invention also provides methods of treating, preventing or ameliorating the symptoms of autoimmune or demyelinat ing disease, in particular MS, in a subject, preferably a human subject, by administering a therapeutically effective amount of said soluble IL-18Rα to the subject.

Abstract translation: 本发明涉及可用于治疗疾病，特别是在人类受试者中的新型治疗性蛋白质。 发明人的结果强烈地支持使用可溶性IL-18Ra来治疗诸如自身免疫性或脱髓鞘性疾病，特别是多发性硬化症（MS）的疾病。 因此，本发明提供了用于治疗自身免疫或脱髓鞘疾病，特别是MS的可溶性IL-18Ra。 本发明还提供了通过向受试者施用治疗有效量的所述可溶性IL-18Rα来治疗，预防或改善受试者，优选人受试者中自身免疫性或脱髓鞘疾病特别是MS的症状的方法。